๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Higher-risk Myelodysplastic Syndromes

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Ascentage Pharma Group Inc. ยท Tests: APG-115, Azacitidine, Cytarabine Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites๐Ÿ“ Duarte๐Ÿ“ Palo Alto๐Ÿ“ Tampa Crossbow Therapeutics, Inc. ยท Tests: CBX-250 CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04493164Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts NCT05365035Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Venetoclax, Azacitidine Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor NCT07238712Phase 21 site๐Ÿ“ Saint Petersburg St. Petersburg State Pavlov Medical University ยท Tests: Ruxolitinib, Abatacept (Orencia) Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS NCT06533761Phase 112 sites๐Ÿ“ Duarte๐Ÿ“ Aurora๐Ÿ“ Tampa Stelexis BioSciences ยท Tests: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA) Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04047641Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cladribine, Cytarabine, Idarubicin, Quizartinib Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome NCT03661307Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Decitabine, Quizartinib, Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta Andrew E. Place, MD ยท Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression NCT07155226Phase 1, Phase 230 sites๐Ÿ“ Decatur๐Ÿ“ New York๐Ÿ“ Chapel Hill AstraZeneca ยท Tests: AZD3632, Posaconazole A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04243785Phase 13 sites๐Ÿ“ Duarte๐Ÿ“ New York๐Ÿ“ Houston Edgewood Oncology Inc. ยท Tests: BTX-A51, Azacitidine Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS NCT07532824Phase 1, Phase 22 sites๐Ÿ“ Prague๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Proton Total Marrow Irradiation Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients NCT06918834Phase 25 sites๐Ÿ“ Beijin๐Ÿ“ Zhengzhou๐Ÿ“ Jinan Institute of Hematology & Blood Diseases Hospital, China ยท Tests: Immediate HSCT Group, Bridging Therapy Group Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies NCT07044544Phase 11 site๐Ÿ“ Birmingham University of Alabama at Birmingham ยท Tests: G-CSF, Decitabine, Venetoclax 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome NCT06287944Phase 11 site๐Ÿ“ Duarte City of Hope Medical Center ยท Tests: Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomograpโ€ฆ A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes NCT06196203Phase 215 sites๐Ÿ“ Los Angeles๐Ÿ“ Aurora๐Ÿ“ New Haven Akeso ยท Tests: AK117, Placebo, Azacitidine Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS NCT04708054Phase 2, Phase 31 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Busulfan, Cladribine, Fludarabine Phosphate, Hematopoietic Cell Transplantation, Thiotepa Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML NCT07723703Phase 11 site๐Ÿ“ Fairfax Amphista Therapeutics Ltd ยท Tests: AMX-883, Posaconazole Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878NA1 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Venetoclax, None-placebo, Busulfan (BU) A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes NCT06146257Phase 18 sites๐Ÿ“ Duarte๐Ÿ“ Irvine๐Ÿ“ Kansas City GluBio Therapeutics Inc. ยท Tests: GLB-001 Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597Phase 1, Phase 239 sites๐Ÿ“ Atlanta๐Ÿ“ Indianapolis๐Ÿ“ Bethesda CellCentric Ltd. ยท Tests: CCS1477, Pomalidomide, Dexamethasone, Azacitidine, Venetoclax Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) NCT05554406Phase 2227 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Tucson National Cancer Institute (NCI) ยท Tests: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer NCT07046078Phase 21 site๐Ÿ“ Seattle Fred Hutchinson Cancer Center ยท Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy,โ€ฆ Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) NCT04184505Phase 346 sites๐Ÿ“ Alessandria๐Ÿ“ Ancona๐Ÿ“ Ascoli Piceno Gruppo Italiano Malattie EMatologiche dell'Adulto ยท Tests: Azacitidine, Standard Chemotherapy, Allogeneic stem cell transplantation Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Edetate Calcium Disodium, Multivitamin, Succimer VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS NCT06471946Phase 1, Phase 21 site๐Ÿ“ Beijing Navy General Hospital, Beijing ยท Tests: Venetoclax Plus Azacytidine Conditioning Regimen Allo-HSCT Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy NCT06439199n/a1 site๐Ÿ“ Nantes Nantes University Hospital Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders NCT03314974Phase 21 site๐Ÿ“ Minneapolis Masonic Cancer Center, University of Minnesota ยท Tests: HSCT with TBI Regimen, HSCT with Non-TBI Regimen
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy